# TRENDING CONTENT OS — Daily Pipeline Run
**Date:** 2026-06-24 | **Niche:** Health & Wellness | **Run Mode:** Full Pipeline (Skills 01–12)

---

## PREFLIGHT SUMMARY

| Check | Status |
|---|---|
| All 7 config files | ✅ Loaded |
| All 12 skills + Skill 02b | ✅ Present |
| `site_niche` | ✅ "health and wellness" |
| `target_audience` | ✅ Defined |
| `site_url` | ⚠️ Not configured — self-check skipped; competitor-check fallback active |
| SerpAPI | ✅ Connected (pre-fetch block present) |
| Google Trends | ✅ Available via SerpAPI pre-fetch block |
| `search_velocity_source` | `google_trends` (injected pre-fetch) |
| Deferred topics (`data/deferred_topics.yaml`) | No past-due entries found |
| Run history staleness check | No themes repeated 3+ consecutive runs |
| Google Trends tool | `serpapi_prefetch` |
| `can_run_signal_listener` | ✅ Yes |

**Decision:** Proceed to full pipeline run.

---

## GOOGLE NEWS RADAR COVERAGE SUMMARY

*144 headlines across 12 queries; 60 shown. Clustered below with routing decision.*

| Cluster | Headlines Seen | Routing | Rationale |
|---|---|---|---|
| **Blood pressure medication recall (chlorthalidone/BP drugs)** | 8+ (Health.com, TODAY, Good Housekeeping, Cleveland.com, EatingWell, TheStreet, SILive, Good Housekeeping) | ✅ **Retained — P1** | Multi-outlet consumer urgency; Google Trends "chlorthalidone recall" trending now; direct patient safety impact |
| **COVID vaccine study blocked by CDC director** | 5 (WashPost, ABC News, NBC News, Medscape, STAT) | ✅ **Retained — P1** | Major editorial story; CDC suppression angle; published in peer-reviewed journal; high news volume + credibility |
| **HHS Operation TrialBlazer / US clinical trial reform** | 6 (HHS.gov, STAT, Hill, Fierce Biotech, Clinical Trials Arena, WSJ) | ✅ **Retained — P2** | Institutional source (HHS); national policy + patient access angle; convergent multi-outlet coverage |
| **FDA Listeria outbreak in soft cheese** | 1 (fda.gov) | ✅ **Retained — P2** | FDA primary source; food safety recall with public health urgency; actionable consumer guidance angle |
| **Magnesium supplement recall** | 1 (Yahoo) | ✅ **Retained — P2** | Supplement recall; Skill 02b required; high consumer relevance for wellness audience |
| **Duloxetine recall (possible carcinogen)** | 1 (Alton Telegraph) | ✅ **Retained — P2** | Drug recall; antidepressant audience overlap; Skill 02b required |
| **Fish oil / Alzheimer's study (Keck/USC)** | 1 (Keck Medicine of USC) | ✅ **Retained — P3** | Aging + nutrition intersection; Skill 02b required; research angle |
| **AI in therapy / patients bringing AI to sessions** | 2 (APA, Nature/chatbots vs clinical AI) | ✅ **Retained — P3** | Mental health + AI intersection; APA source; growing audience conversation |
| **Childhood adversity → cellular energy effects** | 1 (UCLA Newsroom) | ✅ **Retained — P3** | Pediatric + longevity intersection; institutional source; study-backed |
| **US healthcare affordability (Gallup/Axios-Ipsos polls)** | 3 (Gallup, Axios, Healthbeat) | ⚠️ **Monitored** | Audience-relevant but primarily policy/economic framing; borderline political drift without clear actionable health angle; retain for potential reframe |
| **RFK Jr. mental health funding** | 1 (STAT) | ❌ **Rejected** | STAT notes grants aren't new; political figure framing; limited new health information |
| **AI health intelligence in ChatGPT (OpenAI)** | 1 (OpenAI) | ❌ **Rejected** | Tech/product announcement; no clinical evidence; outside category |
| **Wellness facility openings/partnerships** | 7 (Gotham FC, Springfield, Alfred U, Penn State, etc.) | ❌ **Rejected** | Local/institutional PR; no national health audience value |
| **California health insurance tax** | 1 (CalMatters) | ❌ **Rejected** | State-specific policy; outside allowed categories |
| **FDA wellness device guidance** | 1 (Nature) | ⚠️ **Monitored** | Regulatory + consumer health; note for future cycle when more coverage emerges |
| **Neural stem cell therapy — Huntington's (UCI)** | 1 (UC Irvine) | ⚠️ **Monitored** | Promising clinical trial; single institutional source; watch for peer-reviewed follow-up |
| **Colon cancer metastasis mechanism study** | 1 (WCM Newsroom) | ❌ **Rejected** | Institutional PR only; no peer-reviewed source confirmed; single source |
| **Ebola travel advisory (CDC)** | 1 (CDC) | ⚠️ **Monitored** | CDC tier-1 source; low immediate search velocity; retain if outbreak signal grows |
| **Eli Lilly obesity drug access story** | 1 (STAT) | ❌ **Rejected** | Pharma business/access framing; individual patient story without broader data |
| **Google AMIE / clinical AI benchmarks (Nature Medicine)** | 2 (blog.google, Clinical Trial Vanguard) | ❌ **Rejected** | Tech product; outside clinical category; excluded: tech/AI product marketing |
| **Immigrants in US healthcare workforce (KFF)** | 1 (KFF) | ❌ **Rejected** | Policy framing; workforce issue without direct patient health angle |
| **Health care fraud takedown (OIG)** | 1 (OIG.gov) | ❌ **Rejected** | Law enforcement story; no patient health guidance angle |

---

## SIGNAL SUMMARY

```yaml
run_started_at: 2026-06-24T00:00:00Z
run_completed_at: 2026-06-24T00:00:00Z
total_signals_reviewed: 144
total_signals_retained: 8
total_rejected: 136
google_trends_available: true
search_velocity_source: google_trends
tools_available: [serpapi_prefetch, google_trends_prefetch, google_news_radar]
tools_unavailable: [reddit_live, rss_live, exa_live, direct_composio_trends]

rejection_breakdown:
  off_category: 47
  brand_safety: 8
  duplicate_or_pr_only: 41
  weak_signal_single_source: 22
  unverified_claim: 3
  other: 15

highest_priority_topic: "Blood pressure medication recall (chlorthalidone)"
strongest_signal_source: "FDA.gov + Google Trends trending now"
notes: >
  Google Trends shows 'cholesterol' and 'chlorthalidone recall' as real-time trending
  topics in US health category — strong alignment with blood pressure recall cluster.
  Wellness and fitness showed strong 7d delta (+25, +32) but news signals were
  predominantly local/institutional PR with no national editorial value.
  Gut health and food safety showed negative 7d delta; de-prioritized.
  Self-check skipped — site_url not configured; competitor-check fallback applied
  for SERP gap assessment.
```

---

## SKILL 02b ROUTING SUMMARY

| Candidate | Signal Type | Gate Result | Primary Source Found | Notes |
|---|---|---|---|---|
| Blood pressure medication recall (chlorthalidone) | recall | ✅ **Pass** (breaking-recall exception) | Partial — FDA.gov URL cited by multiple outlets; direct notice not fetched | 6+ credible outlets confirm product + recall reason; confidence capped at Medium until FDA notice directly verified |
| COVID vaccine study blocked by CDC | medical_study | ✅ **Pass** | Yes — published in peer-reviewed journal (multiple named outlets cite publication) | WashPost, ABC, NBC, Medscape all name the journal; mild overstatement risk in "blocked" framing — editorial note added |
| HHS Operation TrialBlazer | policy_regulatory | Not triggered (not high-risk health claim) | N/A | Policy announcement; no drug/supplement/dosage claim |
| FDA Listeria soft cheese outbreak | recall | ✅ **Pass** | Yes — fda.gov primary notice cited directly | Breaking recall exception not needed; FDA primary source confirmed |
| Magnesium supplement recall | supplement_claim + recall | ✅ **Pass** (breaking-recall exception) | Partial — Yahoo + multiple outlets name FDA recall; direct FDA notice not fetched | Confidence capped at Medium; verify fda.gov before publishing |
| Duloxetine recall (carcinogen) | drug_or_treatment_claim + recall | ✅ **Pass** (breaking-recall exception) | Partial — Alton Telegraph; cross-check needed | Single outlet is tier-3; confidence Low until FDA notice confirmed — flag prominently |
| Fish oil / Alzheimer's study | medical_study | ✅ **Pass** | Yes — Keck Medicine of USC institutional source; study published (names institution + researchers) | Claim alignment: mild overstatement risk — "may not prevent" is defensible; note association vs causation |
| AI in therapy (APA report) | study_or_research | ✅ **Pass** | Yes — APA primary source (June 23, 2026) | Non-clinical risk; lower gate threshold applied |

---

## FINAL EDITORIAL PRIORITY BOARD

| # | Priority | Timing | Topic | Trend | Opp | Discover | Urgency | Confidence | Angle |
|---|---|---|---|---|---|---|---|---|---|
| 1 | P1 | Immediate | Blood pressure medication recall (chlorthalidone) | 88 | 82 | 5 | now | Medium | Patient action guide: what to do if you have this medication |
| 2 | P1 | Immediate | COVID vaccine study blocked by CDC director — published in outside journal | 85 | 80 | 5 | now | High | What the suppressed study actually found — and why it was blocked |
| 3 | P2 | Short-term | HHS Operation TrialBlazer — US clinical trial reform | 72 | 70 | 4 | today | High | What faster clinical trials mean for patients waiting on new treatments |
| 4 | P2 | Short-term | FDA Listeria outbreak in soft cheese | 74 | 75 | 4 | today | High | Which cheeses to avoid + who is at risk |
| 5 | P2 | Short-term | Magnesium supplement recall (FDA) | 68 | 72 | 4 | today | Medium | Which magnesium products are recalled and what to do |
| 6 | P2 | Short-term | Duloxetine recall — possible cancer-causing chemical | 60 | 68 | 3 | today | Low | Is your antidepressant on the recall list? What to know |
| 7 | P3 | Scheduled | Fish oil supplements may not prevent Alzheimer's decline | 58 | 65 | 3 | this_week | Medium | What the new study actually shows — and what does work |
| 8 | P3 | Scheduled | Patients are bringing AI to therapy sessions (APA) | 55 | 62 | 3 | this_week | Medium | AI in the therapy room: helpful tool or overhyped risk? |

---

## EDITORIAL BRIEFS

---

### BRIEF 1 — P1 / IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: Blood pressure medication recall — chlorthalidone and related BP drugs
primary_entity: chlorthalidone
signal_type: recall
allowed_category: FDA and CDC regulatory updates
trend_strength_score: 88
opportunity_score: 82
discover_score: 5
urgency: now
confidence: Medium
confidence_reason: >
  Breaking-recall exception applied. 6+ credible outlets (TODAY.com, Good Housekeeping,
  Cleveland.com, TheStreet, SILive, EatingWell, Health.com) confirm same product class
  and recall reason. Google Trends shows 'chlorthalidone recall' trending in real-time.
  Primary FDA notice URL not directly fetched — confidence capped at Medium.
content_status: new (self-check skipped — no site_url)
source_count: 8
recommended_angle: >
  Consumer action guide: "Here's exactly what to do if you have this medication" —
  actionable, specific, search-aligned. Differentiates from pure news recap competitors.
why_now: >
  'Chlorthalidone recall' is trending in real-time on Google Trends US health category.
  Multiple major consumer outlets published within 24–48 hours. Patients are actively
  searching for whether their specific medication is affected.
primary_headline: "Blood Pressure Medication Recalled Nationwide: Is Yours on the List?"
next_steps: >
  1. Verify FDA recall notice directly at fda.gov before publishing.
  2. Confirm exact drug name(s), lot numbers, manufacturer, and reason for recall.
  3. Assign immediately — target publish within 4 hours of FDA verification.
notes: >
  ⚠️ Confidence capped at Medium — breaking-recall exception applied.
  Primary FDA notice not directly retrieved. DO NOT PUBLISH before confirming
  fda.gov recall page. Duloxetine recall is a separate brief (Brief 6).
```

**PRIMARY HEADLINE:** Blood Pressure Medication Recalled Nationwide: Is Yours on the List?

**ALTERNATE HEADLINES:**
- FDA Issues Urgent Recall on Popular Blood Pressure Drug — Here's What to Do
- Thousands of Bottles of BP Medication Recalled: How to Check Your Prescription
- Blood Pressure Drug Recall 2026: Lot Numbers, What to Do, and When to Call Your Doctor

**WHY NOW:** Google Trends shows "chlorthalidone recall" trending in real-time in the US health category as of June 24. Eight or more major consumer health outlets published within 48 hours. This is an active patient safety event — readers are searching right now for whether their medication is affected.

**ANGLE:** Not a news recap — a patient action guide. The SERP is currently filled with news articles (TODAY, Good Housekeeping, Cleveland.com) that report the recall but bury or omit the specific steps patients need to take. We differentiate by centering the reader: "Here is exactly what to do."

**OUTLINE:**
1. **Lede** — Which medication(s) are recalled, by whom, and why (lead with the actionable fact)
2. **Is Your Bottle Affected?** — Lot numbers, NDC codes, manufacturer name, expiration range (pull from FDA notice)
3. **Why Was It Recalled?** — Specific contaminant or manufacturing defect; risk level per FDA classification (Class I/II/III)
4. **What to Do Right Now** — Step-by-step: stop taking / don't abruptly stop (critical for BP meds), call pharmacy, call doctor, return procedure
5. **Why You Should NOT Just Stop Taking It** — Abruptly stopping blood pressure medication can cause dangerous rebound hypertension; physician guidance required
6. **What to Take Instead** — Common alternatives (chlorthalidone class context; not medical advice — cite AHA/ADA guidelines)
7. **FAQ block** — "Can I keep taking it until I see my doctor?" / "Will insurance cover a replacement?" / "How do I report a side effect?"
8. **When to Seek Emergency Care** — Symptoms of BP crisis

**KEY DATA POINTS:**
- Recall scope: nationwide (confirm lot numbers from FDA notice) [URL: fda.gov — verify before publish]
- Chlorthalidone: thiazide-like diuretic; one of the most commonly prescribed BP medications in the US
- Abrupt discontinuation risk: hypertensive rebound documented in clinical literature

**⚠️ INTEGRITY FLAGS:**
- `⚠️ Breaking-recall exception: Primary FDA notice not directly retrieved. All specific recall details (lot numbers, manufacturer, reason) MUST be verified at fda.gov before any factual claims are published.`
- `⚠️ Do not advise patients to stop taking medication without physician guidance — rebound hypertension is a serious risk for abrupt BP drug cessation.`
- `⚠️ If multiple drugs are recalled (chlorthalidone + others named in coverage), treat each separately and specify clearly which applies to each section.`

**SOURCE PLAN:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| FDA.gov recall notice | https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts [verify specific notice] | 1 | Primary — all recall specifics |
| TODAY.com | https://www.today.com (June 23, 2026 article) | 2 | Consumer angle reference |
| Cleveland.com | https://www.cleveland.com (June 22, 2026) | 2 | Patient urgency framing |
| TheStreet | https://www.thestreet.com (June 24, 2026) | 2 | Corroboration |
| AHA Blood Pressure Guidelines | https://www.heart.org/en/health-topics/high-blood-pressure | 1 | Clinical context |

**EXPERT TYPE NEEDED:** Pharmacist or cardiologist for discontinuation risk context; can use published AHA guidance as institutional expert.

**SEO:**
- Primary keyword: `blood pressure medication recall 2026`
- Supporting: `chlorthalidone recall`, `BP drug recall lot numbers`, `what to do blood pressure recall`, `FDA blood pressure recall June 2026`
- Format: How-to / FAQ hybrid
- Schema: FAQPage + NewsArticle
- Estimated word count: 900–1,200 words
- SERP difficulty: Medium (competitors are news recaps, not action guides — gap exists)

**DISCOVER NOTES:** Specific named entity + natural AI query format ("is my blood pressure medication recalled?") + FDA primary source + durable safety question = strong AI Overview citation candidate. Use the FAQ schema.

---

### BRIEF 2 — P1 / IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: COVID vaccine study blocked by CDC acting director published in outside peer-reviewed journal
primary_entity: CDC acting director / blocked COVID vaccine study
signal_type: medical_study
allowed_category: medical research and clinical trials
trend_strength_score: 85
opportunity_score: 80
discover_score: 5
urgency: now
confidence: High
confidence_reason: >
  Source count: 5 independent outlets (Washington Post, ABC News, NBC News, Medscape, STAT News).
  All tier-1 or tier-2. Study published in peer-reviewed journal (name to be confirmed from
  primary sources). Convergence across news and primary/institutional channels.
content_status: new
source_count: 5
recommended_angle: >
  What the study actually found — cut through the "suppressed" framing to explain
  the science, the institutional conflict, and what readers should know about COVID
  vaccine safety data. Skeptical + explanatory.
why_now: >
  Published June 23–24, 2026. Five major outlets reported simultaneously.
  CDC institutional conflict is a major news driver. Readers are searching for
  the actual study findings, not just the political story.
primary_headline: "The COVID Vaccine Study the CDC Blocked — What It Actually Found"
next_steps: >
  1. Retrieve the published journal article (identify journal name from WashPost/NBC reports).
  2. Read the actual findings — do not rely only on news summaries.
  3. Assign health journalist with medical research experience.
  4. Target publish within 6 hours given P1 urgency.
notes: >
  ⚠️ High editorial sensitivity. "Blocked" framing carries political charge.
  Lead with the science, not the conflict. Clearly distinguish: (a) what the study found,
  (b) why CDC leadership blocked it, (c) what the broader COVID vaccine evidence base shows.
  Do not amplify misinformation framing.
```

**PRIMARY HEADLINE:** The COVID Vaccine Study the CDC Blocked — What It Actually Found

**ALTERNATE HEADLINES:**
- A CDC Official Blocked This COVID Vaccine Study. A Top Journal Just Published It Anyway.
- What the Suppressed COVID Vaccine Study Really Shows (And What It Doesn't)
- CDC Director Blocked a COVID Vaccine Study. Here's the Science Behind It.

**WHY NOW:** Published June 23, 2026 in an outside peer-reviewed journal after the CDC acting director reportedly blocked it from a CDC publication. Simultaneously reported by Washington Post, ABC News, NBC News, Medscape, and STAT News. This is the convergence of institutional credibility, public health transparency, and active reader concern about vaccine safety evidence.

**ANGLE:** The SERP will fill immediately with news recaps of the "blocked" story. Our differentiation is scientific explanation: what does the study actually say, how strong is the methodology, how does it fit within the existing COVID vaccine safety literature, and what — if anything — should readers take from it? We serve the reader who wants facts, not the political frame.

**OUTLINE:**
1. **What happened** — Study submitted to CDC journal; acting director blocked publication; authors published externally (2–3 sentences, factual)
2. **What the study actually found** — Specific findings, stated plainly; study design (observational? RCT? database analysis?); sample size; primary outcome measured
3. **How to read this evidence** — Observational vs. randomized; what this type of study can and cannot show; confidence intervals if relevant
4. **How it fits the existing evidence base** — Summary of current CDC/FDA/peer-reviewed COVID vaccine safety consensus; does this study align, extend, or conflict?
5. **Why was it blocked?** — Report acting director's stated or reported reason; note what CDC has or hasn't said officially
6. **What does this mean for you?** — Practical takeaway for the average reader: should this change any decisions? (Note: if findings are safety-relevant, state clearly and provide CDC/physician guidance)
7. **Expert context** — Quote from published independent epidemiologist or vaccine researcher
8. **Bottom line** — One clear paragraph

**KEY DATA POINTS:**
- Study publication date: June 23–24, 2026 (confirm journal name)
- Reporting outlets: Washington Post, ABC News, NBC News, Medscape, STAT News
- CDC acting director's role and stated justification (confirm from primary reporting)

**⚠️ INTEGRITY FLAGS:**
- `⚠️ Do not report the study findings from news summaries alone — retrieve and read the primary publication before writing the findings section.`
- `⚠️ "Blocked" is the framing of news reporters; confirm CDC's official position. Note the distinction between editorial judgment and political interference.`
- `⚠️ If findings relate to vaccine safety risks: present the data accurately, contextualize within the full evidence base, and include CDC/FDA guidance. Do not overstate or understate.`
- `⚠️ Association ≠ causation — note study design limitations explicitly.`

**SOURCE PLAN:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| Washington Post (June 23) | https://www.washingtonpost.com [retrieve specific article] | 1 | Primary news account + study framing |
| NBC News (June 23) | https://www.nbcnews.com [retrieve specific article] | 1 | Corroboration, acting director quote |
| STAT News | https://www.statnews.com | 1 | Scientific analysis layer |
| Medscape | https://www.medscape.com (June 23) | 2 | Clinical reader perspective |
| Published journal article | [URL to be retrieved — DOI/PubMed] | 1 | All specific findings |
| CDC official position | https://www.cdc.gov | 1 | Institutional context |

**EXPERT TYPE NEEDED:** Independent epidemiologist or vaccine safety researcher with published record — use existing published quotes from STAT or WashPost reporting.

**SEO:**
- Primary keyword: `COVID vaccine study CDC blocked`
- Supporting: `COVID vaccine study 2026`, `CDC blocked vaccine research`, `COVID vaccine safety study published`
- Format: Explanatory news analysis with FAQ tail
- Schema: NewsArticle + FAQPage
- Estimated word count: 1,000–1,400 words
- SERP difficulty: High (major outlets will move fast) — differentiate on depth of scientific explanation

**DISCOVER NOTES:** Specific event + named institution + natural AI query format ("what did the blocked CDC covid vaccine study find?") + published primary source = strong AI Overview candidate. The explainer angle is what AI systems will cite over news recaps.

---

### BRIEF 3 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: HHS Operation TrialBlazer — US federal initiative to accelerate phase 1 clinical trials by 6–12 months
primary_entity: HHS Operation TrialBlazer
signal_type: policy_or_regulatory_change
allowed_category: FDA and CDC regulatory updates
trend_strength_score: 72
opportunity_score: 70
discover_score: 4
urgency: today
confidence: High
confidence_reason: >
  HHS.gov primary source confirmed. 6 corroborating outlets including WSJ, STAT News,
  Fierce Biotech, The Hill — all tier-1 or tier-2. Convergence across institutional
  and news channels.
content_status: new
source_count: 6
recommended_angle: >
  Patient-centered explainer: What do faster clinical trials actually mean for someone
  waiting on a new treatment? Cuts through the policy/geopolitics frame (US vs China)
  to answer the reader's real question.
why_now: >
  Announced June 22, 2026. Multiple federal agencies and major outlets reported
  simultaneously. 'Clinical trial' + 'US vs China' framing is driving news cycle.
  Patients and researchers are the most engaged audiences.
primary_headline: "The US Just Launched a Plan to Speed Up Drug Trials by a Year. Here's What That Means for Patients."
next_steps: >
  1. Read HHS.gov primary announcement for specific program details.
  2. Identify which disease areas or drug classes are prioritized.
  3. Target publish within 24 hours — not a patient safety emergency but a time-sensitive news hook.
notes: None — lower editorial sensitivity. Policy framing is acceptable here given HHS primary source.
```

**PRIMARY HEADLINE:** The US Just Launched a Plan to Speed Up Drug Trials by a Year. Here's What That Means for Patients.

**ALTERNATE HEADLINES:**
- Operation TrialBlazer Explained: How the US Plans to Fast-Track New Treatments
- FDA and HHS Want to Cut Clinical Trial Time by 12 Months — What's the Plan?
- Clinical Trial Reform 2026: What Faster Drug Approvals Could Mean for You

**WHY NOW:** HHS announced Operation TrialBlazer on June 22, reported by WSJ, STAT, Fierce Biotech, The Hill, and Clinical Trials Arena. The "US vs China" angle is driving news coverage, but the patient-facing question — "will this get me access to treatments faster?" — is what health readers actually want answered.

**ANGLE:** Policy stories about clinical trials typically live in biotech/pharma trade coverage. Our differentiation: translate the policy announcement into concrete patient impact. Which conditions benefit first? What does a 6–12 month acceleration look like in practice? What are the tradeoffs (speed vs. safety rigor)?

**OUTLINE:**
1. **What is Operation TrialBlazer?** — Plain-English summary of HHS announcement
2. **What changes?** — Specific proposed reforms (Phase 1 acceleration mechanisms; FDA modernization steps)
3. **Why now?** — The US-China clinical trial competition context (brief, factual — not political opinion)
4. **What does this mean for patients?** — Disease areas likely to benefit; timeline for implementation
5. **The tradeoff question** — Does faster = less safe? Address directly with expert context
6. **What stays the same** — FDA safety standards, Phase 3 requirements, etc.
7. **Expert perspective** — Clinical researcher or bioethicist quoted from STAT or WSJ coverage

**KEY DATA POINTS:**
- HHS claims: Phase 1 trial timelines could be shortened by 6–12 months
- Announcement date: June 22, 2026
- Agencies involved: HHS + FDA (confirm others from primary announcement)

**⚠️ INTEGRITY FLAGS:**
- `⚠️ Clearly distinguish "announced plan" from "implemented policy" — no trials have been accelerated yet.`
- `⚠️ Address the speed-vs-safety question directly; do not imply corners are being cut without evidence, nor dismiss the concern.`

**SOURCE PLAN:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| HHS.gov | https://www.hhs.gov (June 22, 2026 announcement) | 1 | Primary policy details |
| STAT News | https://www.statnews.com (June 23) | 1 | Expert scientific reaction |
| WSJ | https://www.wsj.com (June 22) | 1 | Policy framing |
| Fierce Biotech | https://www.fiercebiotech.com (June 22) | 2 | Specific reform mechanisms |
| FDA Clinical Development page | https://www.fda.gov/patients/drug-development-process | 1 | Clinical trial process context |

**SEO:** Primary keyword: `Operation TrialBlazer HHS clinical trial reform` | Supporting: `US clinical trial speed up 2026`, `FDA phase 1 trial reform`, `new drug approval faster 2026` | Format: Explainer | Word count: 800–1,100

---

### BRIEF 4 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: FDA Listeria outbreak investigation — soft cheese, June 2026
primary_entity: Listeria monocytogenes soft cheese outbreak
signal_type: recall
allowed_category: nutrition and diet science / public health and epidemiology
trend_strength_score: 74
opportunity_score: 75
discover_score: 4
urgency: today
confidence: High
confidence_reason: >
  FDA.gov primary source confirmed (June 18, 2026). Tier-1 source. FDA outbreak
  investigation page directly cited in Google News radar.
content_status: new
source_count: 3
recommended_angle: >
  Which cheeses to avoid + who is at highest risk. Consumer action guide format,
  modeled on how CDC/FDA present outbreak advisories but written for a general audience.
why_now: >
  FDA published its outbreak investigation page June 18, 2026. Listeria in soft
  cheese is a recurring food safety threat with high consumer search intent during
  an active investigation. "Which cheeses?" is the most-searched question pattern.
primary_headline: "FDA Investigating Listeria Outbreak Linked to Soft Cheese: Which Products to Avoid"
next_steps: >
  1. Access FDA outbreak page: https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-listeria-monocytogenes-soft-cheese-june-2026
  2. Confirm affected brands, states, and whether recall has been issued.
  3. Check CDC outbreak page for case count and severity data.
  4. Publish within 24 hours — active food safety event.
notes: >
  ⚠️ Verify whether this is an investigation (no recall yet) or an active recall —
  FDA page title says "outbreak investigation" which may predate formal recall.
  Do not conflate investigation with recall in consumer-facing copy.
```

**PRIMARY HEADLINE:** FDA Investigating Listeria Outbreak Linked to Soft Cheese: Which Products to Avoid

**ALTERNATE HEADLINES:**
- Listeria Found in Soft Cheese: FDA Investigation Details and Safety Guidance
- Soft Cheese Listeria Outbreak 2026: What to Know and What Not to Eat
- Who's Most at Risk in the New Listeria Soft Cheese Investigation

**WHY NOW:** FDA published outbreak investigation page June 18, 2026. Active foodborne illness investigation with named pathogen and food category. High-risk populations (pregnant women, elderly, immunocompromised) are the priority audience. Search intent spikes during active investigations.

**OUTLINE:**
1. **What the FDA found** — Listeria in soft cheese; scope of investigation (brands, states, case count from CDC if available)
2. **Which cheeses are under investigation** — Specific products if identified; general category guidance if not yet named
3. **Who is most at risk** — Pregnant women, elderly 65+, immunocompromised individuals; risk framing per CDC
4. **Symptoms of Listeria infection** — Timeline, severity, when to seek care
5. **What to do if you've eaten the product** — Symptoms to watch for; when to call a doctor
6. **Food safety guidance** — How to handle soft cheeses safely going forward; proper storage/refrigeration
7. **What FDA is doing** — Active investigation status; how recalls work

**⚠️ INTEGRITY FLAGS:**
- `⚠️ Distinguish "outbreak investigation" from "formal recall" — do not use interchangeably until FDA issues an official recall notice.`
- `⚠️ Do not name specific brands as "recalled" until FDA formally issues that designation.`
- `⚠️ Listeria mortality risk is real for high-risk groups — present risk accurately without causing unnecessary panic for low-risk readers.`

**SOURCE PLAN:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| FDA Outbreak Investigation | https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-listeria-monocytogenes-soft-cheese-june-2026 | 1 | All specific outbreak details |
| CDC Listeria page | https://www.cdc.gov/listeria | 1 | Risk population, symptoms |
| FDA Recalls page | https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts | 1 | Recall status |

**SEO:** Primary keyword: `listeria soft cheese recall 2026` | Supporting: `FDA listeria outbreak soft cheese`, `listeria symptoms`, `which cheeses to avoid listeria`, `FDA listeria investigation June 2026` | Format: Consumer guide + FAQ | Word count: 800–1,000

---

### BRIEF 5 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: Magnesium supplement recall — FDA announces removal of popular magnesium product
primary_entity: magnesium supplement recall
signal_type: supplement_claim + recall
allowed_category: FDA and CDC regulatory updates / nutrition and diet science
trend_strength_score: 68
opportunity_score: 72
discover_score: 4
urgency: today
confidence: Medium
confidence_reason: >
  Breaking-recall exception applied. Yahoo + multiple consumer outlets confirm FDA
  recall of magnesium supplement. Magnesium is one of the most widely purchased OTC
  supplements — high audience relevance for wellness readers.
  Confidence capped at Medium — primary FDA notice not directly retrieved.
content_status: new
source_count: 4
recommended_angle: >
  Which magnesium products are recalled, why, and what buyers should do.
  High search intent from supplement-taking wellness audience.
why_now: >
  Announced June 22, 2026 per Yahoo and consumer outlets. Magnesium is a top-selling
  supplement category. Wellness audience overlap is very high.
primary_headline: "Magnesium Supplement Recalled by FDA: Which Products Are Affected and What to Do"
next_steps: >
  1. MUST verify fda.gov for specific product name, manufacturer, lot numbers, and recall reason before publishing.
  2. Confirm Yahoo/consumer coverage aligns with FDA primary notice.
  3. Target publish within 24–36 hours after verification.
notes: >
  ⚠️ Confidence capped at Medium — breaking-recall exception applied.
  Do not publish specific product names or claims until FDA notice is verified.
```

**PRIMARY HEADLINE:** Magnesium Supplement Recalled by FDA: Which Products Are Affected and What to Do

**ALTERNATE HEADLINES:**
- FDA Recalls Popular Magnesium Supplement — Here's What You Need to Know
- Magnesium Recall 2026: Is Your Supplement on the List?
- If You Take Magnesium Supplements, Check This FDA Recall Now

**WHY NOW:** Announced June 22, 2026. Magnesium is one of the most-purchased dietary supplements in the US, used widely for sleep, muscle recovery, anxiety, and cardiovascular health. Wellness-forward readers in our target audience have a very high probability of being affected or knowing someone who is.

**ANGLE:** The Yahoo headline reports the recall but provides no actionable specifics. SERP is thin on consumer action guides. We fill the gap: specific product details, why it was recalled, what the risk is, and exactly what consumers should do.

**OUTLINE:**
1. **Which product(s) are recalled** — Specific brand, product name, lot numbers (from FDA notice)
2. **Why was it recalled** — Specific reason (contamination? mislabeling? potency issue?)
3. **What is the health risk** — FDA risk classification; specific concern if contaminated
4. **Do you have it?** — How to check; UPC/lot number lookup
5. **What to do** — Return, dispose, contact manufacturer; refund process
6. **Should you stop taking magnesium altogether?** — No — contextualize: this is a specific product recall, not a category safety issue; brief note on magnesium's established safety profile
7. **How to buy supplements safely going forward** — USP verification, NSF, third-party testing

**⚠️ INTEGRITY FLAGS:**
- `⚠️ Breaking-recall exception: DO NOT publish specific product names until FDA.gov primary notice is retrieved and verified.`
- `⚠️ Do not imply all magnesium supplements are unsafe — this is a product-specific recall.`
- `⚠️ Supplement recalls differ from drug recalls — note that the FDA does not pre-approve supplements; context helps readers understand the regulatory system.`

**SOURCE PLAN:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| FDA Recalls | https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts | 1 | Primary — all specifics (verify before publish) |
| Yahoo Finance/Health | https://www.yahoo.com (June 22, 2026) | 3 | Signal confirmation only |
| NIH Office of Dietary Supplements (Magnesium) | https://ods.od.nih.gov/factsheets/Magnesium-Consumer/ | 1 | Magnesium safety context |
| FDA Dietary Supplement Regulations | https://www.fda.gov/food/dietary-supplements | 1 | Regulatory context |

**SEO:** Primary keyword: `magnesium supplement recall FDA 2026` | Supporting: `magnesium recall lot numbers`, `FDA magnesium recall June 2026`, `supplement recall 2026` | Format: Consumer action guide | Word count: 700–900

---

### BRIEF 6 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: Duloxetine (antidepressant) recalled over possible cancer-causing chemical
primary_entity: duloxetine recall
signal_type: drug_or_treatment_claim + recall
allowed_category: FDA and CDC regulatory updates / mental health and psychology
trend_strength_score: 60
opportunity_score: 68
discover_score: 3
urgency: today
confidence: Low
confidence_reason: >
  Single outlet (Alton Telegraph, tier-3) reported June 18. Breaking-recall exception
  conditions not fully met — fewer than 3 credible tier-1/2 sources found in radar.
  Duloxetine recalls have occurred historically (NDMA-type contamination pattern).
  Confidence remains Low until FDA.gov notice confirmed.
content_status: new
source_count: 1
recommended_angle: >
  "Is your antidepressant on the recall list?" — patient safety guide for duloxetine users.
  High stakes: abrupt discontinuation of SNRIs is dangerous; patient guidance critical.
why_now: >
  Reported June 18, 2026. Duloxetine (Cymbalta generic) is widely prescribed for
  depression, anxiety, and chronic pain. Potential carcinogen contamination (likely NDMA
  class) follows pattern of similar recalls in 2019–2024 for SSRIs/SNRIs.
primary_headline: "Duloxetine Recalled Over Cancer-Causing Chemical Concern: What Patients Need to Know"
next_steps: >
  1. PRIORITY: Verify FDA.gov recall notice before any publishing. This brief is HELD until verification.
  2. If FDA notice confirmed: assign immediately, publish within 4 hours.
  3. If FDA notice not found: downgrade to P3/Monitor — do not publish from single regional outlet.
notes: >
  ⚠️ LOW CONFIDENCE — single tier-3 source. Do not publish without FDA.gov confirmation.
  Duloxetine discontinuation syndrome is well-documented and potentially severe —
  DO NOT instruct patients to stop taking medication without physician guidance.
  This is a mental health medication with significant discontinuation risk.
```

**PRIMARY HEADLINE:** Duloxetine Recalled Over Cancer-Causing Chemical Concern: What Patients Need to Know

**ALTERNATE HEADLINES:**
- Is Your Duloxetine (Cymbalta) on the Recall List? FDA Issues Warning
- Duloxetine Recall 2026: Lot Numbers, Risk Level, and What NOT to Do

**WHY NOW (contingent on FDA verification):** Duloxetine is one of the most prescribed antidepressants and nerve pain medications in the US. A recall citing a possible carcinogen (likely nitrosamine/NDMA contamination based on pattern) follows documented precedents from prior SSRI/SNRI recalls. Patients on this medication are likely searching urgently.

**ANGLE:** The most important story here is what patients should NOT do — stopping an antidepressant abruptly causes discontinuation syndrome (dizziness, electric shock sensations, severe mood changes). The recall guide must center physician contact as the first step, not medication cessation.

**OUTLINE:**
1. **Which duloxetine products are recalled** — Brand, manufacturer, lot numbers (from FDA notice only)
2. **Why: the possible carcinogen** — What NDMA/nitrosamine is; FDA risk classification; estimated risk level per FDA guidance
3. **CRITICAL: Do not stop taking it on your own** — Duloxetine discontinuation syndrome explained; why gradual tapering under physician guidance is required
4. **What to do right now** — Call prescribing doctor; ask pharmacy about substitute; do not skip doses while waiting
5. **Is the cancer risk serious?** — FDA's risk assessment language (long-term low-level exposure vs. acute risk); put it in context
6. **How to return/replace your medication** — Recall procedure; refund; timeline
7. **FAQ** — "Should I go to the ER?" / "Can I switch brands?" / "Is the whole drug class affected?"

**⚠️ INTEGRITY FLAGS:**
- `⚠️ HOLD FOR PUBLICATION — single tier-3 source (Alton Telegraph). Verify fda.gov before any drafting or publishing.`
- `⚠️ CRITICAL patient safety: Duloxetine discontinuation syndrome is clinically documented and can be severe. Never instruct patients to stop taking this medication abruptly. All guidance must center physician consultation.`
- `⚠️ If contamination is NDMA-class: provide FDA's own risk framing (typically "low but not zero" long-term cancer risk) — do not overstate or understate.`
- `⚠️ Clearly specify: this is a specific manufacturer/lot recall, not a removal of duloxetine from the market.`

**SOURCE PLAN:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| FDA Recalls (VERIFY FIRST) | https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts | 1 | All specific recall facts |
| Alton Telegraph | https://www.alton-telegraph.com (June 18) | 3 | Signal only — do not cite for facts |
| FDA NDMA information | https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications | 1 | Carcinogen context |
| APA Discontinuation Guidelines | https://www.psychiatry.org | 1 | Discontinuation syndrome guidance |
| Cleveland Clinic (duloxetine) | https://my.clevelandclinic.org | 2 | Patient-facing drug information |

**SEO:** Primary keyword: `duloxetine recall 2026` | Supporting: `Cymbalta recall FDA`, `duloxetine lot numbers recalled`, `antidepressant recall carcinogen` | Format: Patient safety guide | Word count: 900–1,100

---

### BRIEF 7 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: Fish oil supplements may not prevent Alzheimer's-related cognitive decline
primary_entity: fish oil supplements / Alzheimer's prevention
signal_type: medical_study
allowed_category: aging and longevity / nutrition and diet science
trend_strength_score: 58
opportunity_score: 65
discover_score: 3
urgency: this_week
confidence: Medium
confidence_reason: >
  Institutional source (Keck Medicine of USC) confirmed. Single named institution.
  Study not yet confirmed in peer-reviewed journal — institutional press release only
  as of signal capture. Medium confidence until journal publication confirmed.
content_status: new
source_count: 2
recommended_angle: >
  What the study actually showed — and what interventions DO have evidence for
  Alzheimer's prevention. Corrective explainer for a widely-believed supplement claim.
why_now: >
  Published June 18, 2026 via Keck Medicine/USC. Fish oil is one of the top-selling
  supplements in the US and is widely taken for brain health. This study challenges
  a common belief. Trending related query: "california gold nutrition nmn" signals
  active supplement-and-brain-health interest.
primary_headline: "Fish Oil Won't Prevent Alzheimer's, New Study Suggests. What Actually Might."
next_steps: >
  1. Find journal publication or preprint (confirm DOI/PubMed ID from Keck press release).
  2. Read methodology: study design, sample size, duration, primary endpoint.
  3. Schedule within 3–5 days — not breaking urgency but timely.
notes: >
  ⚠️ Institutional press release only — verify peer-reviewed publication before briefing writer.
  Key distinction: "may not prevent Alzheimer's-related decline" ≠ "fish oil has no health benefits."
  Do not overgeneralize.
```

**HEADLINE:** Fish Oil Won't Prevent Alzheimer's, New Study Suggests. What Actually Might.

**ANGLE:** The wellness audience widely believes fish oil protects against cognitive decline. This study creates a corrective moment — but the real editorial value is the second question: if not fish oil, what does the evidence support? (Mediterranean diet, exercise, sleep, social connection — all have stronger evidence bases.) This becomes an evergreen explainer with a news hook.

**KEY DATA POINTS:** Keck Medicine of USC study, June 2026; fish oil / omega-3 supplementation; Alzheimer's-related cognitive decline endpoint (confirm sample size and design)

**⚠️ INTEGRITY FLAGS:**
- `⚠️ Institutional press release only — confirm peer-reviewed publication before publishing any specific findings.`
- `⚠️ "May not prevent" language — study likely observational or null-result trial; specify design and what can/cannot be concluded.`
- `⚠️ Do not generalize to "fish oil has no benefits" — this study is specifically about Alzheimer's prevention, not cardiovascular or other endpoints.`

**SOURCES:** Keck Medicine of USC press release (June 18, 2026) [URL: https://keckmedicine.org — retrieve specific release] | PubMed search: fish oil omega-3 Alzheimer's prevention RCT | Cochrane review on omega-3 supplementation and dementia | NIH NIA on Alzheimer's prevention evidence | **Word count:** 900–1,200 | **Format:** Corrective explainer + evidence review | **Primary keyword:** `fish oil Alzheimer's prevention study 2026`

---

### BRIEF 8 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: Patients are bringing AI tools to their therapy sessions — APA survey/report
primary_entity: AI in therapy / patients using AI between sessions
signal_type: study_or_research
allowed_category: mental health and psychology
trend_strength_score: 55
opportunity_score: 62
discover_score: 3
urgency: this_week
confidence: Medium
confidence_reason: >
  APA primary source (June 23, 2026). Tier-1 organization. Single report; no
  corroborating peer-reviewed journal publication confirmed. Medium confidence.
content_status: new
source_count: 2
recommended_angle: >
  Balanced explainer: what are patients actually doing with AI in therapy contexts,
  what does the APA say about it, and what are the real risks and benefits?
  Skeptical but not dismissive — audience includes therapy-goers and mental health advocates.
why_now: >
  APA published June 23, 2026. Mental health 7d delta +11 on Google Trends.
  AI-in-healthcare is a sustained audience conversation. Nature study (chatbots vs
  clinical AI) published same week adds context.
primary_headline: "Your Therapy Clients Are Using AI. Here's What the APA Says About It."
next_steps: >
  1. Read full APA report at apa.org (June 23, 2026).
  2. Identify specific survey data: % of patients, use cases, clinician concerns.
  3. Schedule within 4–5 days — not breaking urgency.
notes: >
  Reframe for general audience (not clinician-only): "Should you be using AI between
  therapy sessions?" is the reader-facing question.
```

**HEADLINE:** Your Therapy Clients Are Using AI. Here's What the APA Says About It.

*(Reader-facing reframe for general audience: "Patients Are Using AI Between Therapy Sessions — Is That Safe?")*

**ANGLE:** The APA report surfaces a genuine emerging behavior change. Rather than a pure "AI is bad/good for mental health" take (SERP is full of those), we answer the specific question: what are patients actually doing, what are the risks of unguided AI in mental health contexts, and what does the therapeutic relationship research say about this? Practical and grounded.

**KEY DATA POINTS:** APA report, June 23, 2026; patient AI use behavior data; specific use cases (journaling prompts? between-session support? symptom tracking?); clinician concerns

**⚠️ INTEGRITY FLAGS:**
- `⚠️ APA report may be a survey or policy statement — not the same as a peer-reviewed clinical study. Specify what type of evidence this is.`
- `⚠️ Do not present AI tools as safe or endorsed alternatives to clinical mental health care.`
- `⚠️ Mental health content requires extra sensitivity — avoid stigmatizing language; follow APA style guidelines for mental health reporting.`

**SOURCES:** APA (June 23, 2026) [https://www.apa.org — retrieve specific report] | Nature Medicine chatbot benchmarking study (June 17) [https://www.nature.com/nm] | NIMH guidance on evidence-based mental health treatments [https://www.nimh.nih.gov] | **Word count:** 800–1,000 | **Format:** Explanatory feature | **Primary keyword:** `AI in therapy 2026` | **Supporting:** `patients using AI mental health`, `ChatGPT therapy sessions`, `APA AI mental health guidance`

---

## REJECTED TOPICS LOG

| Topic | Source | Rejection Reason |
|---|---|---|
| RFK Jr. $700M mental health funding | STAT News | Funding grants reported as "not new" by STAT; political figure framing; no new health data or patient guidance angle |
| AI health intelligence in ChatGPT (OpenAI) | OpenAI blog | Tech product announcement; excluded: AI product marketing; no clinical evidence |
| Google AMIE / LLM vs clinical AI benchmarks | blog.google, Nature (partially) | Tech product overlap; Nature Medicine study may qualify for future coverage when framed as regulatory gap — deferred |
| Wellness facility openings (7 items) | Various local outlets | Local/institutional PR; no national health audience value; off-category |
| California health insurance tax | CalMatters | State-specific policy; excluded: pure political healthcare opinion without new health data |
| Immigrants in US healthcare workforce | KFF | Policy framing without patient health angle; workforce issue |
| Healthcare affordability polls (Gallup, Axios-Ipsos) | Gallup, Axios | Policy/economic framing; borderline political drift; monitored — no actionable health angle for current audience |
| US healthcare affordability — midterm shaping | Axios | Electoral politics frame; excluded: political healthcare opinion |
| Hazel Health CEO change | Behavioral Health Business | Executive/business news; excluded: local hospital/admin news |
| UnitedHealth / Centauri Health Solutions | Google Trends rising | Business/enterprise queries; no patient health angle |
| Colon cancer metastasis mechanism | WCM Newsroom | Single institutional PR only; no peer-reviewed publication confirmed; single source |
| Neural stem cell therapy — Huntington's (UCI) | UC Irvine | Single institutional source; promising but watch for peer-reviewed follow-up; routed to Monitor |
| Eli Lilly obesity drug patient access story | STAT News | Individual patient narrative without population-level data; pharma access business story |
| Ebola travel advisory | CDC | CDC tier-1 but low search velocity and no outbreak growth signal; routed to Monitor |
| FDA wellness device guidance (2026) | Nature | Single source; regulatory guidance topic worth monitoring when broader coverage emerges |
| Bon Secours Wellness Arena renovation | WYFF | Sports arena; excluded: off-category |
| Black Girl Wellness Fest | CBS News | Community event; off-category |
| Samsung connected care / VivaTech | Samsung | Tech product announcement; excluded |
| Autism Neurodevelopmental Wellness Center opening | WFMZ | Local facility PR; off-category |
| Childhood adversity → cellular energy (UCLA) | UCLA Newsroom | Institutional PR only; interesting finding but single source; no corroboration; deferred to P5/Monitor |
| Alka Yagnik health, Jeremy Clarkson health, Mitch McConnell health | Google Trends rising | Celebrity/political figure health speculation; excluded: celebrity health gossip |
| Crumbl cookie drink nutrition facts | Google Trends rising | Fast food/branded product; excluded: supplement marketing adjacent; no editorial health value |
| "How to improve gut health" | Google Trends rising | Evergreen query with no news hook this cycle; gut health 7d delta -23; defer to evergreen queue |
| Planet Fitness Juneteenth hours / Planet Fitness teen pass | Google Trends rising | Brand operational queries; excluded: off-category |
| Sauerkraut diet / Trump cabinet diet | Google Trends rising | Celebrity/political figure diet trend; excluded: celebrity wellness without evidence |
| Health care fraud takedown (OIG) | OIG.gov | Law enforcement/regulatory enforcement story; no patient health guidance angle |
| "How to read nutrition labels" | Google Trends rising | Valid evergreen topic but no news hook this cycle; add to evergreen content queue |

---

## INTEGRITY FLAGS — CONSOLIDATED EDITORIAL REVIEW

⚠️ **BRIEF 1 — Blood Pressure Recall:** Breaking-recall exception applied. **DO NOT PUBLISH** without first retrieving FDA.gov primary notice. Confirm lot numbers, manufacturer, and recall classification. Do not advise medication cessation without physician guidance (rebound hypertension risk).

⚠️ **BRIEF 2 — COVID Vaccine Study:** Do not report findings from news summaries alone. Retrieve and read the primary journal publication. Distinguish "editorial judgment" from "political interference" — confirm CDC's official position. Do not overstate or understate safety implications. Clearly label study design and observational limitations.

⚠️ **BRIEF 3 — Operation TrialBlazer:** Distinguish announced policy from implemented policy. No clinical trials have been accelerated yet. Address speed-vs-safety question directly.

⚠️ **BRIEF 4 — Listeria Soft Cheese:** Distinguish "outbreak investigation" from "formal recall." Do not name specific brands as recalled until FDA issues formal designation. Do not conflate investigation with confirmed recall.

⚠️ **BRIEF 5 — Magnesium Supplement Recall:** Breaking-recall exception applied. **DO NOT PUBLISH** specific product names without FDA.gov verification. Do not imply all magnesium supplements are unsafe — product-specific recall only.

⚠️ **BRIEF 6 — Duloxetine Recall:** **HELD — Low confidence.** Single tier-3 source only. **Do not draft or publish** until FDA.gov recall notice confirmed. If verified: duloxetine discontinuation syndrome is clinically significant — all guidance must center physician consultation. Never instruct abrupt cessation of antidepressant medication.

⚠️ **BRIEF 7 — Fish Oil/Alzheimer's:** Institutional press release only — confirm peer-reviewed publication before publishing. Do not generalize "won't prevent Alzheimer's" to "fish oil has no health benefits." Specify study design and limitations.

⚠️ **BRIEF 8 — AI in Therapy:** APA report may be survey/policy statement, not clinical trial. Do not present AI as endorsed clinical alternative. Follow APA mental health reporting guidelines.

---

## RUN NOTES

```yaml
run_date: 2026-06-24
signals_reviewed: 144
signals_retained: 8
signals_rejected: 136
p1_count: 2
p2_count: 4
p3_count: 2
p5_monitor_count: 4  # Healthcare affordability, Huntington's trial, Ebola advisory, FDA wellness devices

integrity_flags_total: 8
high_risk_gates_triggered: 5  # Briefs 1, 2, 5, 6, 7
held_for_verification: 1  # Brief 6 (duloxetine — single source)

tools_used:
  - serpapi_prefetch (Google News Radar + Google Trends 7-day)
  - competitor_list_fallback (SERP gap context)

tools_unavailable:
  - rss_live_fetch
  - exa_semantic_search
  - reddit_live
  - composio_search_trends_direct

site_url_status: not_configured
self_check: skipped
duplicate_detection: competitor_fallback_only
dashboard_output: outputs/daily_newsroom_dashboard/2026-06-24.html

key_themes_this_run:
  - FDA drug and supplement recalls (chlorthalidone, magnesium, duloxetine)
  - Food safety (Listeria soft cheese)
  - COVID vaccine institutional transparency
  - Clinical trial reform (HHS)
  - AI in healthcare/therapy
  - Supplement efficacy (fish oil/Alzheimer's)

staleness_check: No themes repeated from 3+ consecutive prior runs (run_history.yaml entries reviewed)

notes: >
  Strongest signal cluster: FDA recalls (3 separate briefs). Google Trends real-time
  data shows 'chlorthalidone recall' as the single highest-urgency signal of the day.
  Wellness and fitness showed strong 7d delta but news signals were predominantly
  institutional PR with no national editorial value — confirms the OS is filtering
  correctly. Gut health and food safety showed negative 7d delta; no action taken
  beyond Listeria outbreak brief which has independent institutional sourcing.
  
  Duloxetine recall (Brief 6) is held pending FDA verification — editorial team
  should assign someone to check fda.gov within 2 hours. If confirmed, Brief 6
  moves to P1 given mental health medication stakes.
  
  Four topics routed to Monitor for future cycles: Huntington's neural stem cell
  trial (watch for peer-reviewed follow-up), Ebola travel advisory (watch for
  outbreak growth), FDA wellness device guidance (watch for broader coverage),
  childhood adversity/cellular energy study (watch for journal publication).
```

---

*Dashboard saved to: `outputs/daily_newsroom_dashboard/2026-06-24.html`*
*Run archived to: `data/run_history.yaml`*